Evidence map›Paper›PMID 38352505›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Selection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously in South-East Asia.

Cecile P G Meier-Scherling, Oliver J Watson, Victor Asua, Isaac Ghinai, Thomas Katairo, Shreeya Garg, Melissa Conrad, Philip J Rosenthal, Lucy C Okell, Jeffrey A Bailey

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Cecile P G Meier-ScherlingCenter for Computational Molecular Biology, Brown University, Providence, RI, USA.ORCID 0000-0002-7833-5164
Oliver J WatsonMedical Research Council Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.ORCID 0000-0003-2374-0741
Victor AsuaInfectious Diseases Research Collaboration, Kampala, Uganda.
Isaac GhinaiOxford University, Oxford, UK.
Thomas KatairoInfectious Diseases Research Collaboration, Kampala, Uganda.
Shreeya GargDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Melissa ConradDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9984-8030
Philip J RosenthalDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7953-7622
Lucy C OkellMedical Research Council Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.
Jeffrey A BaileyCenter for Computational Molecular Biology, Brown University, Providence, RI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Artemisinin partial resistance, mediated by mutations in the Methods: We investigated K13 mutation prevalence at 16 sites in Uganda (2016-2022, 6586 samples), and five sites in SEA (2003-2018, 5465 samples) by calculating selection coefficients using Bayesian mixed-effect linear models. We then tested whether SEA K13 mutation prevalence could have been forecast accurately using up to the first five years of available data and forecast future K13 mutation prevalence in Uganda. Findings: The selection coefficient for the prevalence of relevant K13 mutations (441L, 469F/Y, 561H, 675V) was estimated at s=0·383 (95% CrI: 0·247 - 0·528) per year, a 38% relative prevalence increase. Selection coefficients across Uganda were s=0·968 (0·463 - 1·569) for 441L, s=0·153 (-0·445 - 0·727) for 469F, s=0·222 (-0·011 - 0·398) for 469Y, and s=0·152 (-0·023 - 0·312) for 675V. In SEA, the selection coefficient was s=-0·005 (-0·852 - 0·814) for 539T, s=0·574 (-0·092 - 1·201) for 580Y, and s=0·308 (0·089 - 0·536) for all validated K13 mutations. Forecast prevalences for Uganda assuming constant selection neared fixation (>95% prevalence) within a decade (2028-2033) for combined K13 mutations. Interpretation: The selection of K13 mutations in Uganda was at a comparable rate to that observed in SEA, suggesting K13 mutations may continue to increase quickly in Uganda. Funding: NIH R01AI156267, R01AI075045, and R01AI089674.

Identifiers

PMID38352505
PMCPMC10862983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.